Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A US military perspective.

D D Remund1, E L Sutton

  • 1United States Department of Defense Pharmacoeconomic Center, Fort Sam Houston, TX 78234-5036, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 6, 2006
PubMed
Summary

The US Military Health Services System is revising its lipid-lowering drug guidelines to improve cost-effectiveness and standardize treatments across facilities. These updates aim to optimize pharmacoeconomic strategies for hyperlipidemia management within the military healthcare system.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What works? Interventions to reduce readmission after hip fracture: A rapid review of systematic reviews.

Injury·2021
Same author

A comparison of antihypertensive medication utilization before and after guideline changes using the Department of Defense Prescription Database.

The Annals of pharmacotherapy·1999
Same author

Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker.

Clinical therapeutics·1998
Same author

Collaboration needed to bolster home care.

Hospital topics·1989
Same author

Collaboration needed to bolster home care.

Health progress (Saint Louis, Mo.)·1988
Same author

Reaction energetics of a mutant triosephosphate isomerase in which the active-site glutamate has been changed to aspartate.

Biochemistry·1986

Area of Science:

  • Pharmacoeconomics
  • Health Services Research
  • Cardiovascular Medicine

Background:

  • The United States (US) Military Health Services System manages lipid therapy decisions for approximately 8.2 million beneficiaries.
  • Annual pharmacy expenditure on lipid-lowering drugs within the system is substantial, ranging from $45-$50 million out of a total $680 million.
  • Current guidelines, established in 1995, are being revised to incorporate new lipid-lowering therapies and research findings.

Purpose of the Study:

  • To discuss lipid therapy decision-making at a population level within the US Military Health Services System.
  • To outline the role of the Department of Defense Pharmacoeconomic Center (PEC) in managing drug formularies and treatment guidelines.
  • To describe proposed changes in formulary management aimed at standardizing drug availability and reducing costs.

Related Experiment Videos

Main Methods:

  • Analysis of current lipid therapy decision-making processes within the military healthcare system.
  • Review of the functions of the Department of Defense Pharmacoeconomic Center (PEC) in cost-effectiveness analysis and formulary establishment.
  • Examination of proposed revisions to the Tri-Service Drug Formulary and Medical Treatment Facility (MTF) outpatient formulary management.

Main Results:

  • The PEC plays a central role in cost-effectiveness analyses and establishing drug formulary lists.
  • Existing hyperlipidemia treatment guidelines are undergoing revision to reflect advancements in lipid-lowering therapies.
  • Proposed changes include a Basic Core List and Master Pharmaceutical Agent List to standardize drug availability and leverage market share.

Conclusions:

  • Revisions to lipid-lowering drug guidelines and formulary management are essential for optimizing pharmacoeconomic strategies.
  • Standardizing drug availability across military facilities can lead to significant cost savings.
  • The updated guidelines aim to improve the cost-effectiveness of hyperlipidemia treatment within the US Military Health Services System.